Articles tagged with Cancer Cells
KAIST researchers have discovered a new way cancer 'hijacks' the blueprint for blood vessel development to fuel its growth. By reactivating a pre-existing gene regulatory program, tumors can drive angiogenesis without evolving entirely new mechanisms.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.
A research team from the University of Liège uncovered a previously unrecognized mechanism that promotes cancer cell survival under therapeutic pressure. Cancer cells reprogram their lipid metabolism to sustain proliferation, with key enzyme SCD1 cooperating with epigenetic regulator HDAC2 to support tumor growth.
Researchers found that GATA6 expression is reduced in liver metastases, correlating with poorer clinical outcomes. Losing GATA6 allows cancer cells to change their identity and become more adaptable, leading to metastasis.
Researchers developed a metal-free carbon monoxide prodrug that significantly reduced metastatic tumor growth in pancreatic and triple-negative breast cancer models without signs of toxicity. The prodrug, CO-116, works by disrupting a signaling pathway that promotes cancer cell migration and metastasis.
Researchers have developed a new method that can detect cancer with low levels of DNA in the blood, providing more detailed information about tumour composition. This could lead to better care for cancer patients, enabling closer monitoring of treatment progress and more informed decision-making.
Researchers discover that breast cancer cells exploit protective systems in bone marrow to remain dormant, using Notch2 signaling and genes like CXCR4 and TIE2. This dormancy allows cells to reactivate years later, leading to secondary tumors.
Researchers have tested a new experimental cancer drug called gamitrinib in its first-in-human study. Gamitrinib is designed to target the mitochondria of cancer cells, where it can disrupt their energy systems.
Researchers from University of Galway developed an AI accelerated computational model to investigate the theory behind why physical forces slow cancer growth. The study suggests that harnessing pressure on a tumor could open new roles for treatments known as mechanotherapies.
A new study by UC3M researchers reveals how extracellular acidosis destabilizes microtubules, the 'avenues' that organize internal cellular traffic, leading to disruptions in cellular function. This finding holds significant implications for understanding pathologies like cancer, diabetes, and certain infectious processes.
A Dartmouth Cancer Center study reveals that the location of immune cells within a tumor can determine whether they aid or hinder the anti-cancer response. Macrophages, often seen as helpful in clearing debris, have been found to play complex roles depending on their location and signals produced.
Researchers identified four distinct mutational clusters in oral cancers lacking traditional risk factors, with two linked to endogenous processes and unique driver gene mutations. The study suggests a potential role of the oral microbiome in tumor development and highlights opportunities for precision medicine approaches.
Researchers have discovered that precursor lesions in the pancreas, often considered a step towards cancer, do not undergo malignant transformation if they lack a specific microenvironment. The team used advanced technologies to isolate and analyze single cells from over 150 donated pancreases, finding that the microenvironment surroun...
Scientists at the Garvan Institute of Medical Research captured 'housekeeping' immune cells actively attacking and engulfing live melanoma cells. These macrophages patrol the edges of melanoma tumours, steadily engulfing cancer cells and slowing tumour growth. The discovery has big implications for immunotherapy.
Researchers have identified a hidden mechanism explaining why breast cancer can return years after successful treatment. Slow-growing breast cancer cells can form microscopic tumours that silently tick away in distant organs, evading detection for decades.
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
Researchers discovered that activated T cells secrete vesicles carrying DNA that enters immune and tumor cells to enhance the immune response against tumors. Preclinical experiments showed that this approach can boost T cell attacks against tumors and improve treatment outcomes.
Researchers examined two mechanisms of whole genome duplication in cells, finding that cytokinesis failure leads to more stable and viable cells, while mitotic slippage results in uneven chromosome distribution and reduced viability. The study suggests targeting chromosome separation could help limit survival of abnormal cells.
Researchers visualize immune synapse and cytotoxic granules with unprecedented level of detail, revealing new perspectives in immuno-oncology. The study uses cryo-expansion microscopy to provide a near-native view of T lymphocyte mechanisms.
A new study from Tulane University found that extra sets of chromosomes in tumor cells make them more mobile and likely to engulf neighboring cells. This stress response triggers an abundance of proteins, reprogramming the cells for motility and phagocytosis.
Researchers at DZNE discovered complex, situation-dependent interactions between glioblastoma cells and microglia in the brain. The study found that microglial activity changes as tumors spread, influencing containment and spread of the disease.
A new method called scSurvival uses single-cell genetic data to identify which cells inside a tumor are most strongly linked to patient survival. The approach pinpoints harmful and helpful cell populations that can drive disease progression, enabling better understanding of why patients with the same cancer have different outcomes.
A study by the CNIO group has identified a genetic signature in precancerous breast lesions that can predict which ones will evolve into invasive tumours. This discovery could help avoid over-treatment of women diagnosed with ductal carcinoma in situ, a common precancerous lesion.
A specific protein, PKC-eta, has been identified as a central driver of aggressive breast cancer cell migration and metastasis. Reducing PKC-eta activity significantly slows tumor growth and reduces metastatic spread in laboratory and animal models.
The Cancer Dependency Map Consortium is launching Phase 3 to expand its research beyond cancer vulnerabilities to investigate resistance and surface targets. The consortium aims to develop novel oncology targets and biomarkers for the next generation of cancer therapies.
Researchers identified a CRISPR variant that distinguishes tumor DNA from healthy DNA and selectively cuts the former. This method relies on methyl groups attached to DNA, which are altered in cancer cells.
A new study co-led by OHSU scientist Catherine Galbraith introduces a series of fluorescent dyes that enable the observation of dynamic biological processes in living cells. These tools allow scientists to study cancer-related processes, such as DNA packaging and gene expression, in real-time.
A University of Calgary-led study found that multiple myeloma tumour cells adapt in multiple ways to become resistant to treatment, highlighting the need for personalized cancer therapy. The research aims to develop next-generation treatments designed to anticipate and overcome these changes.
Researchers generated a comprehensive view of DNA methylation abnormalities in human MDS HSCs, uncovering a novel TET2-GFI1 axis that suppresses malignant transformation. The study identifies key hematopoietic regulators and provides a panoramic view of DNA methylation disruption in MDS.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
Researchers have discovered a new method to make cancer cells more visible to the immune system by blocking NMD, allowing faulty RNA to be used by cells to produce abnormal proteins. This increased visibility of antigens on cancer cells could improve immunotherapy response rates and lead to better outcomes for patients.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
A redesigned endoscope, called CAFE, offers a new way to detect early signs of ovarian cancer by combining high-resolution imaging with gentle cell collection. The device successfully imaged fallopian tube tissue and collected large numbers of epithelial cells, suggesting its potential for earlier disease detection.
Researchers have developed a potential non-invasive treatment for melanoma using a stretchy, heat-activated skin patch that releases copper ions to kill cancer cells. The patch reduced melanoma lesions by 97% in a preliminary animal study, with no damage to surrounding tissue.
Researchers used machine learning methods to identify safe time windows for outpatient stem cell therapy in multiple myeloma patients. The study found that this approach can predict adverse events and enable more precise risk assessment.
Researchers at OHSU have discovered a previously unknown system of internal 'trade winds' that help cells rapidly move essential proteins to the front of the cell. This breakthrough reveals that cells don't rely on random diffusion but instead create targeted streams of fluid to push proteins forward.
A team of researchers has created a 3D model of pediatric brain tumors using biopsy-derived organoids, allowing for more accurate testing of new drugs. The model, which accurately reproduces the human environment, preserves the molecular characteristics of the original tumor and maintains cellular heterogeneity.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
A recent study found that women have a 21% lower risk of death compared to men, but a 12% higher risk of severe side effects from cancer treatment. The research, conducted in partnership with international collaborators, analyzed data from over 20,000 cancer patients and identified sex-based differences in survival and treatment toxicity.
Researchers have discovered that vitamin B2 protects cancer cells from ferroptosis, a type of programmed cell death. By targeting vitamin B2 metabolism, cancer cells may become more susceptible to ferroptosis, paving the way for new cancer therapies.
Researchers at UCSF have discovered a new therapeutic target, SRC, present on up to half of all tumors, which can be targeted with antibody drugs. The enzyme, normally hidden inside cells, is exposed on the surface of tumor cells due to an overactive disposal system, making it an easy target for cancer-killing antibodies.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...
Cancer cell-derived small extracellular vesicles can be excreted into urine, according to researchers who tracked their journey in mouse models. The study reveals that glomerular cells actively transport sEVs across the filtration barrier, supporting their use in emerging urine-based cancer diagnostics.
The study discovered that restoring cellular vibration decreases cancer growth and severity in laryngeal cancer. Researchers exposed cancer cells to sound-wave vibration, leading to a decrease in a protein promoting cancer growth.
Researchers developed an AI-based liquid biopsy test that detects early liver fibrosis and cirrhosis, and reveals signals of broader chronic disease burden. The test uses genome-wide cell-free DNA fragmentation patterns and repeat landscapes to identify disease-specific signatures.
Researchers at Ohio University discovered that blocking the growth hormone receptor may help make lung cancer treatments more effective. Patients with low GHR tumors survived significantly longer than those with high GHR tumors, highlighting a potential new target for therapy.
Scientists developed a new platform using protein-like polymers to target and degrade cancer-driving proteins like MYC and KRAS. The approach triggers cancer cell death, offering hope for treating aggressive and drug-resistant cancers.
A new study suggests that switching to a second treatment while a tumor is still responding to the first may improve cure rates. The 'kick it while it's down' approach targets small tumors and has been shown to be successful in other contexts, such as combatting antibiotic resistance.
Ovarian cancer cells recruit protective mesothelial cells in abdominal fluid to form hybrid cell clusters that resist chemotherapy. These clusters use spike-like structures called invadopodia to invade surrounding tissue. The discovery opens new treatment possibilities and could help doctors monitor disease progression.
A new study suggests blocking key protein p300 can create novel form of cellular stress in cancer cells, re-sensitizing chemo-resistant tumors. Cells produce proteins even with damaged DNA, leading to toxic buildup and stress inside the cell's internal quality-control system.
Researchers at the University of Virginia Health System have identified a molecule that blocks the gene responsible for glioblastoma, a fast-growing and deadly brain cancer. The compound shows promise in preventing the invasive cancer from spreading through the brain without causing harm to healthy tissue.
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to treat multiple solid tumors. The 4-1BB-containing CAR design emerged as superior, demonstrating strongest anti-tumor activity and persistence.
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Researchers identify a protein, PAF15, as a natural brake that prevents DNA replication from becoming overloaded and protects cells from the replication catastrophe. In cancer cells, high levels of PAF15 may create a vulnerability for targeting rapidly dividing tumor cells.
Researchers identified a targetable driver of brain metastases in inflammatory breast cancer, promoting tumor invasion and triggering brain inflammation via the CXCR2 signaling pathway. Targeting sEcad or the CXCR2 pathway may treat or prevent brain metastasis.